| Apr 24 |
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
| Apr 17 |
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
|
| Apr 4 |
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
|
| Apr 3 |
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
|
| Mar 13 |
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Mar 11 |
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
|
| Feb 26 |
Travere Therapeutics to Present at Upcoming Investor Conferences
|
| Feb 23 |
Travere Therapeutics gains as EU backs kidney disease therapy
|
| Feb 23 |
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
|
| Feb 23 |
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
|
